Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning
暂无分享,去创建一个
Eytan Ruppin | Andrew I Su | Ren Sun | Sebastian Burgstaller-Muehlbacher | Peter G Schultz | Sumit K Chanda | Lars Pache | Adolfo García-Sastre | Xin Yin | Peter Teriete | Christopher Benner | S. Chanda | E. Ruppin | A. Su | P. Schultz | R. Sun | J. Chan | K. Yuen | C. Benner | Jeffrey R. Johnson | L. Riva | T. Zwaka | S. Burgstaller-Muehlbacher | R. Albrecht | A. García-Sastre | A. Mesecar | L. Pache | Shuofeng Yuan | V. Poon | L. Miorin | Laura Martin-Sancho | Wen-Chun Liu | P. Teriete | M. Schotsaert | K. White | A. Chatterjee | R. Glynne | Kristina M Herbert | L. Martínez-Sobrido | Paul D. De Jesus | M. Hull | K. Cheng | Kwok-Yung Yuen | Laura Riva | Shuofeng Yuan | Laura Martin-Sancho | Naoko Matsunaga | Paul D De Jesus | Mitchell V Hull | Max W Chang | Jasper Fuk-Woo Chan | Jianli Cao | Vincent Kwok-Man Poon | Kuoyuan Cheng | Tu-Trinh H Nguyen | Andrey Rubanov | Yuan Pu | Courtney Nguyen | Angela Choi | Raveen Rathnasinghe | Michael Schotsaert | Lisa Miorin | Marion Dejosez | Thomas P Zwaka | Ko-Yung Sit | Luis Martinez-Sobrido | Wen-Chun Liu | Kris M White | Mackenzie E Chapman | Emma K Lendy | Richard J Glynne | Randy Albrecht | Andrew D Mesecar | Jeffrey R Johnson | Arnab K Chatterjee | Mackenzie E. Chapman | E. Lendy | Xin Yin | R. Rathnasinghe | Kristina M. Herbert | Mitchell V. Hull | N. Matsunaga | Yuan Pu | Jianli Cao | A. Choi | Ko-Yung Sit | M. Chang | A. Rubanov | C. Nguyen | M. Déjosez | Tu-Trinh H. Nguyen | Sebastian Burgstaller-Muehlbacher | Lisa Miorin | Kuoyuan Cheng
[1] Michael W. Wilson,et al. X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases , 2014, Journal of medicinal chemistry.
[2] K.-C. Chou,et al. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy , 2006, Amino Acids.
[3] L. Björck,et al. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus , 1990, Journal of virology.
[4] J. Dubois,et al. Pharmacokinetics of clofazimine in healthy volunteers. , 1987, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.
[5] Dong Yang,et al. Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[7] T. Reinheckel,et al. Cathepsin B & L Are Not Required for Ebola Virus Replication , 2012, PLoS neglected tropical diseases.
[8] P. Odgren,et al. Snx10 and PIKfyve are required for lysosome formation in osteoclasts , 2020, Journal of cellular biochemistry.
[9] A. Nabar,et al. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society , 2020, Indian Pacing and Electrophysiology Journal.
[10] Q. Deng,et al. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence , 2020, Travel Medicine and Infectious Disease.
[11] A. Shisheva,et al. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation , 2018, PloS one.
[12] C. Schiffer,et al. Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C InfectionPublished as part of the Biochemistry series "Biochemistry to Bedside". , 2017, Biochemistry.
[13] C. January,et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. , 1998, Molecular pharmacology.
[14] Nicholas P. Tatonetti,et al. Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions , 2020, bioRxiv.
[15] Olga Tanaseichuk,et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.
[16] William A. Lee,et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.
[17] Catherine M. Brown,et al. First 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020, medRxiv.
[18] I. Olafsson,et al. Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor , 1989, Nature.
[19] D. Henning. Metabolism , 1972, Introduction to a Phenomenology of Life.
[20] P. Tak,et al. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. , 2009, Arthritis and rheumatism.
[21] R. Guha,et al. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection , 2017, PLoS neglected tropical diseases.
[22] M. Marsh. Faculty Opinions recommendation of Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[23] N. Clumeck,et al. Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion , 1992, Antimicrobial Agents and Chemotherapy.
[24] Jeffrey A. Porter,et al. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling. , 2013, Chemistry & biology.
[25] J. Garrelts,et al. Clofazimine: A Review of its Use in Leprosy and Mycobacterium Avium Complex Infection , 1991, DICP : the annals of pharmacotherapy.
[26] Y. Sakurai,et al. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment , 2015, Science.
[27] Paul Beckett,et al. Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. , 2017, Blood.
[28] N. Kosaka,et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. , 1998, Japanese journal of pharmacology.
[29] F. Achike,et al. Tetrandrine and related bis-benzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action. , 2002, Acta pharmacologica Sinica.
[30] Fumihiro Kato,et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells , 2020, Proceedings of the National Academy of Sciences.
[31] Roberto Maroldi,et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.
[32] J. Treanor,et al. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles. , 2006, Journal of medicinal chemistry.
[33] P. Ferenci. New anti-HCV drug combinations: who will benefit? , 2017, The Lancet. Infectious diseases.
[34] A. Billich. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. , 2007, IDrugs : the investigational drugs journal.
[35] Weiliang Zhu,et al. Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 Cells , 2020 .
[36] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[37] A. Finazzi-Agro’,et al. Protein‐radical enzymes , 1993, FEBS letters.
[38] S. Diamond,et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[39] G. Kobinger,et al. Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry. , 2018, Virology.
[40] R. Pauwels,et al. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. , 1991, Antiviral research.
[41] Peter G. Schultz,et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis , 2015, Proceedings of the National Academy of Sciences.
[42] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] G. Simmons,et al. Development of novel entry inhibitors targeting emerging viruses , 2012, Expert review of anti-infective therapy.
[44] M. Whitt. Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. , 2010, Journal of Virological Methods.
[45] Wentao Fu,et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication , 2008, Proceedings of the National Academy of Sciences.
[46] P. Ferrante,et al. The Use of Antimalarial Drugs against Viral Infection , 2020, Microorganisms.
[47] Paul W Smith,et al. SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2′methyl-4′-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): A novel, potent and selective 5-HT1B receptor antagonist , 2006, Neuropharmacology.
[48] T. Spector,et al. Safety and efficacy of the cathepsin K inhibitor ONO‐5334 in postmenopausal osteoporosis: The OCEAN study , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[49] P. Blumberg,et al. Screening TRPV1 antagonists for the treatment of pain: lessons learned over a decade , 2009, Expert opinion on drug discovery.
[50] Hideki Yamamoto,et al. Discovery of DS-6930, a potent selective PPARγ modulator. Part II: Lead optimization. , 2018, Bioorganic & medicinal chemistry.
[51] R. D’Aquila,et al. Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs , 2020 .
[52] M. Boccadoro,et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. , 2007, Blood.
[53] Li Wang,et al. First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients , 2020, medRxiv.
[54] V. Gribkoff,et al. Phenotypic Alteration of a Human BK (hSlo) Channel byhSloβ Subunit Coexpression: Changes in Blocker Sensitivity, Activation/Relaxation and Inactivation Kinetics, and Protein Kinase A Modulation , 1996, The Journal of Neuroscience.
[55] P. Schultz,et al. Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis , 2017, Proceedings of the National Academy of Sciences.
[56] Jeremy G. Carlton,et al. The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport , 2006, Journal of Cell Science.
[57] C. I. Bliss. THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .
[58] J. Kuhn,et al. The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors. , 2019, Antiviral research.
[59] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[60] Dong Yang,et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target , 2019, Nature Communications.
[61] S. Nishikawa,et al. Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. , 2011, Bone.
[62] Helga Thorvaldsdóttir,et al. Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..
[63] Laura E Niklason,et al. Human iPS cell-derived alveolar epithelium repopulates lung extracellular matrix. , 2013, Journal of Clinical Investigation.
[64] Maria Elena Bottazzi,et al. The SARS-CoV-2 Vaccine Pipeline: an Overview , 2020, Current Tropical Medicine Reports.
[65] T. Cihlar,et al. Current status and prospects of HIV treatment. , 2016, Current opinion in virology.
[66] Analysis of Resistance of Ebola Virus Glycoprotein-Driven Entry Against MDL28170, An Inhibitor of Cysteine Cathepsins , 2019, Pathogens.
[67] M. Seong,et al. Virus Isolation from the First Patient with SARS-CoV-2 in Korea , 2020, Journal of Korean medical science.
[68] Y. Malik,et al. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using in silico Structure-Based Virtual Screening Approach , 2020, Frontiers in Immunology.
[69] Debbie C. Mulhearn,et al. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors , 2008, Bioorganic & Medicinal Chemistry Letters.
[70] Kwok-Hung Chan,et al. Consistent Detection of 2019 Novel Coronavirus in Saliva , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[71] Y. Matsuura,et al. Processing of Capsid Protein by Cathepsin L Plays a Crucial Role in Replication of Japanese Encephalitis Virus in Neural and Macrophage Cells , 2007, Journal of Virology.
[72] Jindrich Cinatl,et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.
[73] Steven J. M. Jones,et al. Drug repositioning for personalized medicine , 2012, Genome Medicine.
[74] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[75] D. Kotton,et al. Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells , 2019, Nature Protocols.
[76] C. Davis,et al. Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. , 2009, Journal of medicinal chemistry.
[77] Hideki Yamamoto,et al. Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification. , 2018, Bioorganic & medicinal chemistry.
[78] K. Chibale,et al. Multistage Antiplasmodium Activity of Astemizole Analogues and Inhibition of Hemozoin Formation as a Contributor to Their Mode of Action. , 2018, ACS infectious diseases.
[79] O. Tsang,et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study , 2020, The Lancet Microbe.
[80] H. Schätzl,et al. Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain , 2012, Journal of Virology.
[81] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[82] P. Woster,et al. Recent advances in the development of polyamine analogues as antitumor agents. , 2009, Journal of medicinal chemistry.
[83] Andrew I. Su,et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis , 2018, Proceedings of the National Academy of Sciences.
[84] T. Spector,et al. Effect of ONO‐5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2‐Year Results From the OCEAN Study , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[85] R. Eastell,et al. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis , 2017, BMC Musculoskeletal Disorders.
[86] P. Schultz,et al. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis , 2017, PLoS neglected tropical diseases.
[87] S. Lo,et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.
[88] P. Workman,et al. In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. , 1993, British Journal of Cancer.
[89] D. Pe’er,et al. A Single-cell Atlas of the Human Healthy Airways. , 2020, American journal of respiratory and critical care medicine.